Kodiak KSI-101 Shows Strong MESI Clinical Trial Results
Palo Alto, California, United States | May 1, 2026 Kodiak Sciences Inc. has announced new clinical and pipeline advancements...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
Palo Alto, California, United States | May 1, 2026 Kodiak Sciences Inc. has announced new clinical and pipeline advancements...
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
